A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

BACKGROUND: Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient treatment for acute leukemia. The primary objective of this phase I single center open label study was to determine the maximum tolerated dose (MTD) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Fabian, Wunderle, Lydia, Badura, Susanne, Schleyer, Eberhard, Brüggemann, Monika, Serve, Hubert, Schnittger, Susanne, Gökbuget, Nicola, Pfeifer, Heike, Wagner, Sebastian, Ashelford, Kevin, Bug, Gesine, Ottmann, Oliver G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523358/
https://www.ncbi.nlm.nih.gov/pubmed/32993794
http://dx.doi.org/10.1186/s40360-020-00446-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523358/
https://www.ncbi.nlm.nih.gov/pubmed/32993794
http://dx.doi.org/10.1186/s40360-020-00446-x

Ejemplares similares